HEMATOLOGY

During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses the adverse events, like capillary leak syndrome, that come with the use of tagraxofusp when treating patients with blastic plasmacytoid dendritic cell neoplasm in the second article of a 2-part series.

Results from the ASTREON trial showed a similar safety profile of oral azacitidine at a dose of 200-mg and 300-mg in patients with lower- to intermediate-risk MDS.

The FDA granted a regenerative medicine advanced therapy designation to TSC-100 and TSC-101 for hematologic malignancies based on encouraging ALLOHA trial data, offering expedited development and review.

Among patients with Ph-positive chronic phase chronic myeloid leukemia, asciminib demonstrated positive results, including a better major molecular response rate at 48 weeks vs investigator-selected TKIs.

In part 2 of our 3-part series, antibody-drug conjugates like enfortumab vedotin and tisotumab vedotin offer novel options for difficult-to-treat tumors.

Guillermo Garcia-Manero, MD, discusses the design and outcomes of the phase 3 COMMANDS trial in patients with low-risk myelodysplastic syndromes.

Doris Hansen, MD, discusses the efficacy of daratumumab, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone in newly diagnosed myeloma.

In an interview with Targeted Oncology, Daniel Nguyen, MD, PhD, further discussed the findings from this phase 2 trial and the potential of vibecotamab.

In part 1 of our 3-part series, antibody-drug conjugates are revolutionizing oncology, targeting cancer cells precisely. Agents like T-DM1, T-DXd, and sacituzumab govitecan continue to change the field.

Valentina Ardila, MD, encouraged further research to understand the complex interplay between obesity, immune response, and transplant outcomes.

During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses why he recommends tagraxofusp-exrs for patients with blastic plasmacytoid dendritic cell neoplasm in need of treatment in the first article of a 2-part series.

In his closing remarks, Yi-Bin Chen, MD, shares his aspirations for the future of graft versus host disease management, emphasizing the need for further clinical trials aimed at replacing steroids as the first-line treatment approach.

In this expert analysis of the AGAVE-201 trial data, the efficacy of a monoclonal antibody in treating graft versus host disease is discussed, with the lowest dose of 0.3 mg/kg administered every 2 weeks demonstrating the highest response rates, exceeding 75%.

The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.

This segment covers the diagnosis and initial treatment of a case of severe, multi-organ cGvHD, including the use of high-dose corticosteroids and other systemic agents.

This segment of the virtual tumor board presentation focuses on the clinical development and use of emerging therapies, specifically Belumosudil, for the management of chronic graft-versus-host disease (cGvHD) following hematopoietic stem cell transplantation.

Dr. Kuykendall provides his perspective on the biggest unmet needs with current advanced PV therapies, emerging data he is following that may impact future management, and any other clinical pearls for optimal PV management.

Dr. Kuykendall discusses the important quality of life aspects to consider when treating PV patients and the specific strategies or treatments he uses to help preserve overall QoL throughout the disease course.

Dr. Kuykendall explains how he monitors PV patients for thrombosis risk, which hematological values concern him most, and his approach if hematocrit rises above 45%.

Dr. Kuykendall shares his experience using peginterferon or ropeginterferon for PV treatment, including the biggest challenges, limitations, and managing safety/tolerability issues with these agents.

Dr. Kuykendall discusses the efficacy and safety findings from studies like MAJIC-PV and PROUD-PV, and how they influence his treatment choices for PV.

Dr. Kuykendall comments on the high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in the RESPONSE trial for hydroxyurea-resistant/intolerant PV, and how these efficacy findings inform his treatment choices.

Dr. Kuykendall explains the factors he considers when deciding on initial therapy for advanced PV patients, including comorbidities, individual patient factors like age and symptoms, and weighing the risks and benefits of different treatment options.

Dr. Kuykendall discusses his initial impressions of the case, how it compares to typical advanced polycythemia vera presentations, and typical risk factors seen in PV patients.

Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging data he is closely following.